Caris Life Sciences Raises $830 Million in Growth Equity Capital to Continue to Expand its Precision Medicine Platform
May 14, 2021
Tags:
The Caris Molecular Intelligence approach allows oncologists to assess all 22,000 genes in both DNA and RNA, utilizing whole exome sequencing, whole transcriptome sequencing, protein analysis, and proprietary AI models and signatures. This
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
.svg)
